Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib

BACKGROUND: Lenvatinib (E7080), an oral multi-kinase inhibitor, has inhibitory action on tumor cell proliferation and tumor angiogenesis in preclinical models. We evaluated correlations between pharmacodynamic (PD) biomarkers with patient clinical outcomes in a lenvatinib phase 1 dose-escalation stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Koyama, Noriyuki, Saito, Kenichi, Nishioka, Yuki, Yusa, Wataru, Yamamoto, Noboru, Yamada, Yasuhide, Nokihara, Hiroshi, Koizumi, Fumiaki, Nishio, Kazuto, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223557/
https://www.ncbi.nlm.nih.gov/pubmed/25047123
http://dx.doi.org/10.1186/1471-2407-14-530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223557/
https://www.ncbi.nlm.nih.gov/pubmed/25047123
http://dx.doi.org/10.1186/1471-2407-14-530

Ejemplares similares